Oxford-based Brainomix, an organization pioneering AI-powered imaging instruments in stroke and lung fibrosis, in the present day introduced the completion of a €16.7 million Sequence C funding spherical to increase to the U.S.
The spherical is co-led by distinguished HealthTech buyers that embody current buyers, Parkwalk Advisors, the UK’s largest progress EIS fund supervisor, and the Boehringer Ingelheim Enterprise Fund (BIVF), together with new investor Hostplus by way of the IP Group Hostplus Innovation Fund. The spherical was supported by LifeSci Capital.
Dr Michalis Papadakis, CEO and Co-founder at Brainomix, mentioned: “We want to thank all of the buyers that participated, together with Parkwalk and Boehringer Ingelheim Enterprise Fund for his or her continued assist, and welcome Hostplus, all of whom recognise the transformative affect that our expertise can have on remedy for stroke and lung fibrosis sufferers. We’ll proceed to harness our place and expertise as a European market chief to realize broad success within the US, serving to enhance affected person care and entry to life-changing therapies.”
A spinout from the College of Oxford, Brainomix was based in 2024 and now operates in additional than 20 international locations globally, together with the US.
It has pioneered the event of an AI platform, Brainomix 360 Stroke, that automates validated imaging biomarkers to enhance each analysis and remedy choices. Brainomix’s NICE-endorsed expertise has been deployed to greater than 300 hospitals, having reportedly benefitted greater than 1.5 million sufferers.
In accordance with the corporate, they’ve demosntrated a novel means to affect remedy charges, with outcomes displaying that Brainomix 360 Stroke was related to an extra 50% improve within the variety of sufferers receiving mechanical thrombectomy, a life-changing stroke remedy decreasing incapacity.
Science Minister Lord Vallance, mentioned: “The AI instruments developed by Brainomix are already serving to sufferers get quick and correct analysis and remedy for a spread of significant situations. Securing this funding will assist them to develop, create extra jobs, and assist extra sufferers. This isn’t solely an instance of a superb college spinout, but in addition proof of how the deep pool of tech and life sciences experience present in Oxford, and throughout the nation, is drawing funding into the UK, driving progress, and supporting our Plan for Change.”
This new funding will allow Brainomix to speed up its industrial growth into the US, the place the corporate has not too long ago secured ten FDA clearances. Recent funding may even assist Brainomix to advance its portfolio of AI-powered expertise in new areas, facilitating quicker analysis and rising entry to life-saving therapies.
Having grown to an organization of greater than 75 employees, Brainomix plans to increase each its Oxford-based operations and international industrial staff.
John Pearson, Chief Funding Officer at Parkwalk, mentioned: “The potential for AI-powered platforms in healthcare to revolutionise analysis and remedy choices is obvious. Brainomix has efficiently demonstrated its platform imaging software program is ready to ship each vital societal affect and robust progress for buyers. Parkwalk is worked up to proceed supporting an organization that’s creating complete options to vital wants and implementing them at scale.”
Brainomix has utilized its AI experience to lung fibrosis, with the event and FDA clearance of its Brainomix 360 e-Lung expertise to precisely predict the development of the illness. The corporate has an ongoing partnership with Boehringer Ingelheim, the worldwide chief in lung fibrosis therapies, to guage the real-world affect of e-Lung to enhance the identification and entry to remedy for individuals with progressive lung fibrosis.
Dr Oliver Reuss, Funding Supervisor of the Boehringer Ingelheim Enterprise Fund (BIVF) and Director of the Brainomix Board, mentioned: “Brainomix has demonstrated an unparalleled monitor file of efficiently delivering AI options into stroke scientific follow, and they’re now doing it once more in lung fibrosis. As a strategic investor with a shared imaginative and prescient to boost look after lung illness, we consider Brainomix has the potential to enhance the identification and entry to remedy for individuals with lung fibrosis.”
